Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study

By Gaynor Paula J.   Gopal Murali   Zheng Wei   Martinez James M.   Robinson Michael J.   Hann Danette   Marangell Lauren B.  

Current Medical Research and Opinion, Vol. 27, Iss. 10, 2011-10 ,pp. : 1859-1867

Informa Healthcare

Access to resources Recommend Favorite

Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial

By  

Psychotherapy and Psychosomatics, Vol. 81, Iss. 5, 2012-08 ,pp. : 312-314

Karger

Access to resources Recommend Favorite

The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder

By Fishbain David A.   Detke Michael J.   Wernicke Joachim   Chappell Amy S.   Kajdasz Daniel K.  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3105-3115

Informa Healthcare

Access to resources Recommend Favorite

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

By Pigott Teresa A.   Prakash Apurva   Arnold Lesley M.   Aaronson Scott T.   Mallinckrodt Craig H.   Wohlreich Madelaine M.  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1303-1318

Informa Healthcare

Access to resources Recommend Favorite

Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite